This technology brief demonstrates the performance of the Xevo™ G2-XS QTof platform for intact level quantification of trastuzumab monoclonal antibody and the use of UNIFI™ for rapid data processing and analysis. In the present study, a monoclonal antibody, trastuzumab, was quantified at the intact level through integration of XICs, which follows common practice in small molecule and peptide bioanalysis.
Title | Format | File Size |
---|---|---|
720006379EN | 1085.47kB |